Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Unknown × NSCLC × osimertinib × Clear all

Phase

Status

Unknown 2 Recruiting 2 Completed 2 Active not recruiting 2 Withdrawn 1 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 26 Lung Neoplasms 5 NSCLC 2 Meningeal Carcinomatosis 2 Bronchial Neoplasms 2 Brain Neoplasms 2 Non-Small Cell Lung Cancer With EGFR T790M Mutation 1 Neurocognitive 1 Advanced Non-small Cell Lung Cancer 1

Interventions

Gefitinib 5 icotinib 4 apatinib 3 anlotinib 3 Pemetrexed 3 Erlotinib Hydrochloride 3 Docetaxel 3 osimertinib 2 dacomitinib 2 camrelizumab 2 aflutinib 2 Thalidomide 2 Drug Therapy 2 Carboplatin 2 Afatinib 2 spartalizumab 1 pembrolizumab 1 nimotuzumab 1 envafolimab 1 Vinorelbine 1 Tyrosine Kinase Inhibitors 1 S 1 (combination) 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Cisplatin 1 Bevacizumab 1 Axitinib 1 Aspirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04811001 2023-02-21

CAPLAND

Fondazione Ricerca Traslazionale

Phase 2 Unknown

NSCLC

NCT04575415 2020-10-20

BELLA

Guangdong Association of Clinical Trials

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡